ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,317.59
-0.26%
Dow Jones
39,069.59
0.01%
Gold vs US Dollar
2,334.20
0.00%
Brent Oil
81.965
0.00%
Bitcoin
68,701.99
0.25%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AVEO Pharmaceuticals Inc (AVEO) Share Price

AVEO AVEO Pharmaceuticals Inc

15.00
0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 AVEO Pharmaceuticals Inc NASDAQ:AVEO NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 15.00 14.99 15.00 0.00 0.00   00:00:00   
 Type  Size  Price  Time  Units 
   0.00  
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore AVEO News
28/03/202419:22GLOBECORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
25/03/202412:10GLOBEAVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
06/02/202413:10GLOBEAVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
16/01/202412:30GLOBEAVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Period
Draw mode
Data Downloads for AVEO

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest AVEO Pharmaceuticals Inc Articles